Seminars in Immunopathology

, Volume 34, Issue 2, pp 185–200 | Cite as

Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

  • Steven Y. C. Tong
  • Luke F. Chen
  • Vance G. FowlerJr


Staphylococcus aureus is a human commensal that can also cause a broad spectrum of clinical disease. Factors associated with clinical disease are myriad and dynamic and include pathogen virulence, antimicrobial resistance, and host susceptibility. Additionally, infection control measures aimed at the environmental niches of S. aureus and therapeutic advances continue to impact upon the incidence and outcomes of staphylococcal infections. This review article focuses on the clinical relevance of advances in our understanding of staphylococcal colonization, virulence, host susceptibility, and therapeutics. Over the past decade key developments have arisen. First, rates of nosocomial methicillin-resistant S. aureus (MRSA) infections have significantly declined in many countries. Second, we have made great strides in our understanding of the molecular pathogenesis of S. aureus in general and community-associated MRSA in particular. Third, host risk factors for invasive staphylococcal infections, such as advancing age, increasing numbers of invasive medical interventions, and a growing proportion of patients with healthcare contact, remain dynamic. Finally, several new antimicrobial agents active against MRSA have become available for clinical use. Humans and S. aureus co-exist, and the dynamic interface between host, pathogen, and our attempts to influence these interactions will continue to rapidly change. Although progress has been made in the past decade, we are likely to face further surprises such as the recent waves of community-associated MRSA.


Staphylococcus aureus Methicillin-resistant MRSA Epidemiology Pathogenesis Treatment 



Dr. Tong is supported by an Australian National Health and Medical Research Council Postdoctoral Training Fellowship (508829), an Australian-American Fulbright Scholarship, and a Royal Australasian College of Physicians Bayer Australia Medical Research Fellowship. Dr. Chen is a co-investigator in the Centers for Disease Control and Prevention and Duke University Prevention Epicenter Program. Dr. Fowler was supported by K24-AI093969 and R01-AI068804.


  1. 1.
    Chambers HF, Deleo FR (2009) Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7(9):629–641PubMedGoogle Scholar
  2. 2.
    Fridkin SK, Hageman JC, Morrison M, Sanza LT, Como-Sabetti K, Jernigan JA, Harriman K, Harrison LH, Lynfield R, Farley MM (2005) Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352(14):1436–1444PubMedGoogle Scholar
  3. 3.
    Purcell K, Fergie J (2005) Epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections: a 14-year study at Driscoll Children’s Hospital. Arch Pediatr Adolesc Med 159(10):980–985PubMedGoogle Scholar
  4. 4.
    Kaplan SL, Hulten KG, Gonzalez BE, Hammerman WA, Lamberth L, Versalovic J, Mason EO Jr (2005) Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 40(12):1785–1791PubMedGoogle Scholar
  5. 5.
    Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, Enright MC, O’Hanlon SJ, Thomas JC, Perdreau-Remington F, Gordon S, Gunthorpe H, Jacobs R, Jensen P, Leoung G, Rumack JS, Chambers HF (2008) A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004–2005. Clin Infect Dis 46(11):1637–1646PubMedGoogle Scholar
  6. 6.
    Tong SY, Bishop EJ, Lilliebridge RA, Cheng AC, Spasova-Penkova Z, Holt DC, Giffard PM, McDonald MI, Currie BJ, Boutlis CS (2009) Community-associated strains of methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus in indigenous northern Australia: epidemiology and outcomes. J Infect Dis 199(10):1461–1470PubMedGoogle Scholar
  7. 7.
    Centers for Disease Control and Prevention (1999) Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus— Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep 48(32):707–710Google Scholar
  8. 8.
    Adem PV, Montgomery CP, Husain AN, Koogler TK, Arangelovich V, Humilier M, Boyle-Vavra S, Daum RS (2005) Staphylococcus aureus sepsis and the Waterhouse–Friderichsen syndrome in children. N Engl J Med 353(12):1245–1251PubMedGoogle Scholar
  9. 9.
    Gillet Y, Issartel B, Vanhems P, Fournet JC, Lina G, Bes M, Vandenesch F, Piemont Y, Brousse N, Floret D, Etienne J (2002) Association between Staphylococcus aureus strains carrying gene for Panton–Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359(9308):753–759PubMedGoogle Scholar
  10. 10.
    Tong SY, Anstey NM, Lum GD, Lilliebridge RA, Stephens DP, Currie BJ (2008) Fatal community-associated methicillin-resistant Staphylococcus aureus pneumonia after influenza. Med J Aust 188(1):61PubMedGoogle Scholar
  11. 11.
    Turnidge JD, Kotsanas D, Munckhof W, Roberts S, Bennett CM, Nimmo GR, Coombs GW, Murray RJ, Howden B, Johnson PD, Dowling K (2009) Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust 191(7):368–373PubMedGoogle Scholar
  12. 12.
    Barber M, Rozwadowska-Dowzenko M (1948) Infection by penicillin-resistant staphylococci. Lancet 2(6530):641–644PubMedGoogle Scholar
  13. 13.
    Rountree PM, Beard MA (1958) Further observations on infection with phage type 80 staphylococci in Australia. Med J Aust 45(24):789–795PubMedGoogle Scholar
  14. 14.
    Jevons MP (1961) “Celbenin”-resistant staphylococci. Br Med J 1:124–125Google Scholar
  15. 15.
    Lina G, Durand G, Berchich C, Short B, Meugnier H, Vandenesch F, Etienne J, Enright MC (2006) Staphylococcal chromosome cassette evolution in Staphylococcus aureus inferred from ccr gene complex sequence typing analysis. Clin Microbiol Infect 12(12):1175–1184PubMedGoogle Scholar
  16. 16.
    Rountree PM, Freeman BM (1955) Infections caused by a particular phage type of Staphylococcus aureus. Med J Aust 42(5):157–161PubMedGoogle Scholar
  17. 17.
    McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC (2003) Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 41(11):5113–5120PubMedGoogle Scholar
  18. 18.
    Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG (2000) Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 38(3):1008–1015PubMedGoogle Scholar
  19. 19.
    Shopsin B, Gomez M, Montgomery SO, Smith DH, Waddington M, Dodge DE, Bost DA, Riehman M, Naidich S, Kreiswirth BN (1999) Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol 37(11):3556–3563PubMedGoogle Scholar
  20. 20.
    Harris SR, Feil EJ, Holden MT, Quail MA, Nickerson EK, Chantratita N, Gardete S, Tavares A, Day N, Lindsay JA, Edgeworth JD, de Lencastre H, Parkhill J, Peacock SJ, Bentley SD (2010) Evolution of MRSA during hospital transmission and intercontinental spread. Science 327(5964):469–474PubMedGoogle Scholar
  21. 21.
    Feil EJ, Li BC, Aanensen DM, Hanage WP, Spratt BG (2004) eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 186(5):1518–1530PubMedGoogle Scholar
  22. 22.
    Willems RJ, Hanage WP, Bessen DE, Feil EJ (2011) Population biology of Gram-positive pathogens: high-risk clones for dissemination of antibiotic resistance. FEMS Microbiol Rev 35(5):872–900PubMedGoogle Scholar
  23. 23.
    Lindsay JA, Holden MT (2006) Understanding the rise of the superbug: investigation of the evolution and genomic variation of Staphylococcus aureus. Funct Integr Genom 6(3):186–201Google Scholar
  24. 24.
    O’Brien FG, Lim TT, Chong FN, Coombs GW, Enright MC, Robinson DA, Monk A, Said-Salim B, Kreiswirth BN, Grubb WB (2004) Diversity among community isolates of methicillin-resistant Staphylococcus aureus in Australia. J Clin Microbiol 42(7):3185–3190PubMedGoogle Scholar
  25. 25.
    Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F (2008) Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 148(4):249–257PubMedGoogle Scholar
  26. 26.
    Eriksen NH, Espersen F, Rosdahl VT, Jensen K (1995) Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol Infect 115(1):51–60PubMedGoogle Scholar
  27. 27.
    VandenBergh MF, Yzerman EP, van Belkum A, Boelens HA, Sijmons M, Verbrugh HA (1999) Follow-up of Staphylococcus aureus nasal carriage after 8 years: redefining the persistent carrier state. J Clin Microbiol 37(10):3133–3140PubMedGoogle Scholar
  28. 28.
    Luzar MA, Coles GA, Faller B, Slingeneyer A, Dah GD, Briat C, Wone C, Knefati Y, Kessler M, Peluso F (1990) Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N Engl J Med 322(8):505–509PubMedGoogle Scholar
  29. 29.
    Kluytmans JA, Mouton JW, Ijzerman EP, Vandenbroucke-Grauls CM, Maat AW, Wagenvoort JH, Verbrugh HA (1995) Nasal carriage of Staphylococcus aureus as a major risk factor for wound infections after cardiac surgery. J Infect Dis 171(1):216–219PubMedGoogle Scholar
  30. 30.
    von Eiff C, Becker K, Machka K, Stammer H, Peters G (2001) Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group. N Engl J Med 344(1):11–16Google Scholar
  31. 31.
    Wertheim HF, Vos MC, Ott A, van Belkum A, Voss A, Kluytmans JA, van Keulen PH, Vandenbroucke-Grauls CM, Meester MH, Verbrugh HA (2004) Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 364(9435):703–705PubMedGoogle Scholar
  32. 32.
    Yang ES, Tan J, Eells S, Rieg G, Tagudar G, Miller LG (2010) Body site colonization in patients with community-associated methicillin-resistant Staphylococcus aureus and other types of S. aureus skin infections. Clin Microbiol Infect 16(5):425–431PubMedGoogle Scholar
  33. 33.
    Faden H, Lesse AJ, Trask J, Hill JA, Hess DJ, Dryja D, Lee YH (2010) Importance of colonization site in the current epidemic of staphylococcal skin abscesses. Pediatrics 125(3):e618–e624PubMedGoogle Scholar
  34. 34.
    Mertz D, Frei R, Periat N, Zimmerli M, Battegay M, Fluckiger U, Widmer AF (2009) Exclusive Staphylococcus aureus throat carriage: at-risk populations. Arch Intern Med 169(2):172–178PubMedGoogle Scholar
  35. 35.
    Uhlemann AC, Knox J, Miller M, Hafer C, Vasquez G, Ryan M, Vavagiakis P, Shi Q, Lowy FD (2011) The Environment as an unrecognized reservoir for community-associated methicillin resistant Staphylococcus aureus USA300: a case–control study. PLoS One 6(7):e22407PubMedGoogle Scholar
  36. 36.
    Batra R, Eziefula AC, Wyncoll D, Edgeworth J (2008) Throat and rectal swabs may have an important role in MRSA screening of critically ill patients. Intensive Care Med 34(9):1703–1706PubMedGoogle Scholar
  37. 37.
    Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D’Agata EM (2003) Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis 37(12):1629–1638PubMedGoogle Scholar
  38. 38.
    Walsh EE, Greene L, Kirshner R (2011) Sustained reduction in methicillin-resistant Staphylococcus aureus wound infections after cardiothoracic surgery. Arch Intern Med 171(1):68–73PubMedGoogle Scholar
  39. 39.
    Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, Roosendaal R, Troelstra A, Box AT, Voss A, van der Tweel I, van Belkum A, Verbrugh HA, Vos MC (2010) Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med 362(1):9–17PubMedGoogle Scholar
  40. 40.
    Robicsek A, Beaumont JL, Paule SM, Hacek DM, Thomson RB Jr, Kaul KL, King P, Peterson LR (2008) Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 148(6):409–418PubMedGoogle Scholar
  41. 41.
    Jain R, Kralovic SM, Evans ME, Ambrose M, Simbartl LA, Obrosky DS, Render ML, Freyberg RW, Jernigan JA, Muder RR, Miller LJ, Roselle GA (2011) Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections. N Engl J Med 364(15):1419–1430PubMedGoogle Scholar
  42. 42.
    Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK (2009) Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997–2007. JAMA 301(7):727–736PubMedGoogle Scholar
  43. 43.
    Kallen AJ, Mu Y, Bulens S, Reingold A, Petit S, Gershman K, Ray SM, Harrison LH, Lynfield R, Dumyati G, Townes JM, Schaffner W, Patel PR, Fridkin SK (2010) Health care-associated invasive MRSA infections, 2005–2008. JAMA 304(6):641–648PubMedGoogle Scholar
  44. 44.
    Edgeworth JD (2011) Has decolonization played a central role in the decline in UK methicillin-resistant Staphylococcus aureus transmission? A focus on evidence from intensive care. J Antimicrob Chemother 66(Suppl 2):ii41–ii47PubMedGoogle Scholar
  45. 45.
    Jarlier V, Trystram D, Brun-Buisson C, Fournier S, Carbonne A, Marty L, Andremont A, Arlet G, Buu-Hoi A, Carlet J, Decre D, Gottot S, Gutmann L, Joly-Guillou ML, Legrand P, Nicolas-Chanoine MH, Soussy CJ, Wolf M, Lucet JC, Aggoune M, Brucker G, Regnier B (2010) Curbing methicillin-resistant Staphylococcus aureus in 38 French hospitals through a 15-year institutional control program. Arch Intern Med 170(6):552–559PubMedGoogle Scholar
  46. 46.
    Vos MC, Behrendt MD, Melles DC, Mollema FP, de Groot W, Parlevliet G, Ott A, Horst-Kreft D, van Belkum A, Verbrugh HA (2009) 5 years of experience implementing a methicillin-resistant Staphylococcus aureus search and destroy policy at the largest university medical center in the Netherlands. Infect Control Hosp Epidemiol 30(10):977–984PubMedGoogle Scholar
  47. 47.
    Grayson ML, Jarvie LJ, Martin R, Johnson PD, Jodoin ME, McMullan C, Gregory RH, Bellis K, Cunnington K, Wilson FL, Quin D, Kelly AM (2008) Significant reductions in methicillin-resistant Staphylococcus aureus bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. Med J Aust 188(11):633–640PubMedGoogle Scholar
  48. 48.
    Huskins WC, Huckabee CM, O’Grady NP, Murray P, Kopetskie H, Zimmer L, Walker ME, Sinkowitz-Cochran RL, Jernigan JA, Samore M, Wallace D, Goldmann DA (2011) Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med 364(15):1407–1418PubMedGoogle Scholar
  49. 49.
    Harbarth S, Fankhauser C, Schrenzel J, Christenson J, Gervaz P, Bandiera-Clerc C, Renzi G, Vernaz N, Sax H, Pittet D (2008) Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 299(10):1149–1157PubMedGoogle Scholar
  50. 50.
    Mostofsky E, Lipsitch M, Regev-Yochay G (2011) Is methicillin-resistant Staphylococcus aureus replacing methicillin-susceptible S. aureus? J Antimicrob Chemother 66(10):2199–2214PubMedGoogle Scholar
  51. 51.
    Tong SY, McDonald MI, Holt DC, Currie BJ (2008) Global implications of the emergence of community-associated methicillin-resistant Staphylococcus aureus in indigenous populations. Clin Infect Dis 46(12):1871–1878PubMedGoogle Scholar
  52. 52.
    Ellis MW, Griffith ME, Dooley DP, McLean JC, Jorgensen JH, Patterson JE, Davis KA, Hawley JS, Regules JA, Rivard RG, Gray PJ, Ceremuga JM, Dejoseph MA, Hospenthal DR (2007) Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 51(10):3591–3598PubMedGoogle Scholar
  53. 53.
    Garza D, Sungar G, Johnston T, Rolston B, Ferguson JD, Matheson GO (2009) Ineffectiveness of surveillance to control community-acquired methicillin-resistant Staphylococcus aureus in a professional football team. Clin J Sport Med 19(6):498–501PubMedGoogle Scholar
  54. 54.
    Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Vandenesch F, Etienne J (1999) Involvement of Panton–Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 29(5):1128–1132PubMedGoogle Scholar
  55. 55.
    Dohin B, Gillet Y, Kohler R, Lina G, Vandenesch F, Vanhems P, Floret D, Etienne J (2007) Pediatric bone and joint infections caused by Panton–Valentine leukocidin-positive Staphylococcus aureus. Pediatr Infect Dis J 26(11):1042–1048PubMedGoogle Scholar
  56. 56.
    Centers for Disease Control and Prevention (2007) Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza—Louisiana and Georgia, December 2006–January 2007. MMWR Morb Mortal Wkly Rep 56(14):325–329Google Scholar
  57. 57.
    Swaminathan A, Massasso D, Gotis-Graham I, Gosbell I (2006) Fulminant methicillin-sensitive Staphylococcus aureus infection in a healthy adolescent, highlighting ‘Panton–Valentine leucocidin syndrome’. Intern Med J 36(11):744–747PubMedGoogle Scholar
  58. 58.
    Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, Etienne J (2007) Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton–Valentine leukocidin. Clin Infect Dis 45(3):315–321PubMedGoogle Scholar
  59. 59.
    Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Cai M, Hansel NN, Perl T, Ticehurst JR, Carroll K, Thomas DL, Nuermberger E, Bartlett JG (2005) Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton–Valentine leukocidin genes. Clin Infect Dis 40(1):100–107PubMedGoogle Scholar
  60. 60.
    Nimmo GR, Coombs GW, Pearson JC, O’Brien FG, Christiansen KJ, Turnidge JD, Gosbell IB, Collignon P, McLaws ML (2006) Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med J Aust 184(8):384–388PubMedGoogle Scholar
  61. 61.
    Tong SY, Lilliebridge RA, Bishop EJ, Cheng AC, Holt DC, McDonald MI, Giffard PM, Currie BJ, Boutlis CS (2010) Clinical correlates of Panton–Valentine leukocidin (PVL), PVL isoforms, and clonal complex in the Staphylococcus aureus population of Northern Australia. J Infect Dis 202(5):760–769PubMedGoogle Scholar
  62. 62.
    Munckhof WJ, Nimmo GR, Carney J, Schooneveldt JM, Huygens F, Inman-Bamber J, Tong E, Morton A, Giffard P (2008) Methicillin-susceptible, non-multiresistant methicillin-resistant and multiresistant methicillin-resistant Staphylococcus aureus infections: a clinical, epidemiological and microbiological comparative study. Eur J Clin Microbiol Infect Dis 27(5):355–364PubMedGoogle Scholar
  63. 63.
    Nimmo GR, Schooneveldt JM, Sutherland JL, Power S, Olesen D, Selvey C, Beard F, Jones M, Paterson DL (2010) Epidemiology of non-multiresistant methicillin-resistant Staphylococcus aureus infection in Queensland, Australia: associations with indigenous populations and Panton–Valentine leukocidin. Eur J Clin Microbiol Infect Dis 29(10):1253–1259PubMedGoogle Scholar
  64. 64.
    Wehrhahn MC, Robinson JO, Pearson JC, O’Brien FG, Tan HL, Coombs GW, Pascoe EM, Lee R, Salvaris P, Salvaris R, New D, Murray RJ (2010) Clinical and laboratory features of invasive community-onset methicillin-resistant Staphylococcus aureus infection: a prospective case–control study. Eur J Clin Microbiol Infect Dis 29(8):1025–1033PubMedGoogle Scholar
  65. 65.
    Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Stryjewski ME, Federspiel JJ, Tonthat GT, Rude TH, Barriere SL, Corey R, Fowler VG Jr (2008) Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol 46(2):678–684PubMedGoogle Scholar
  66. 66.
    Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, Genter FC, Corey GR, Fowler VG Jr (2009) Presence of genes encoding the Panton–Valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. J Clin Microbiol 47(12):3952–3957PubMedGoogle Scholar
  67. 67.
    Peyrani P, Allen M, Wiemken TL, Haque NZ, Zervos MJ, Ford KD, Scerpella EG, Mangino JE, Kett DH, Ramirez JA (2011) Severity of disease and clinical outcomes in patients with hospital-acquired pneumonia due to methicillin-resistant Staphylococcus aureus strains not influenced by the presence of the Panton–Valentine leukocidin gene. Clin Infect Dis 53(8):766–771PubMedGoogle Scholar
  68. 68.
    Nickerson EK, Wuthiekanun V, Wongsuvan G, Limmathurosakul D, Srisamang P, Mahavanakul W, Thaipadungpanit J, Shah KR, Arayawichanont A, Amornchai P, Thanwisai A, Day NP, Peacock SJ (2009) Factors predicting and reducing mortality in patients with invasive Staphylococcus aureus disease in a developing country. PLoS One 4(8):e6512PubMedGoogle Scholar
  69. 69.
    Labandeira-Rey M, Couzon F, Boisset S, Brown EL, Bes M, Benito Y, Barbu EM, Vazquez V, Hook M, Etienne J, Vandenesch F, Bowden MG (2007) Staphylococcus aureus Panton–Valentine leukocidin causes necrotizing pneumonia. Science 315(5815):1130–1133PubMedGoogle Scholar
  70. 70.
    Villaruz AE, Bubeck Wardenburg J, Khan BA, Whitney AR, Sturdevant DE, Gardner DJ, DeLeo FR, Otto M (2009) A point mutation in the agr locus rather than expression of the Panton–Valentine leukocidin caused previously reported phenotypes in Staphylococcus aureus pneumonia and gene regulation. J Infect Dis 200(5):724–734PubMedGoogle Scholar
  71. 71.
    Gladstone GP, Van Heyningen WE (1957) Staphylococcal leucocidins. Br J Exp Pathol 38(2):123–137PubMedGoogle Scholar
  72. 72.
    Szmigielski S, Prevost G, Monteil H, Colin DA, Jeljaszewicz J (1999) Leukocidal toxins of staphylococci. Zentralbl Bakteriol 289(2):185–201PubMedGoogle Scholar
  73. 73.
    Hongo I, Baba T, Oishi K, Morimoto Y, Ito T, Hiramatsu K (2009) Phenol-soluble modulin alpha 3 enhances the human neutrophil lysis mediated by Panton–Valentine leukocidin. J Infect Dis 200(5):715–723PubMedGoogle Scholar
  74. 74.
    Loffler B, Hussain M, Grundmeier M, Bruck M, Holzinger D, Varga G, Roth J, Kahl BC, Proctor RA, Peters G (2010) Staphylococcus aureus Panton–Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog 6(1):e1000715PubMedGoogle Scholar
  75. 75.
    Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, Long RD, Dorward DW, Gardner DJ, Lina G, Kreiswirth BN, DeLeo FR (2006) Is Panton–Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 194(12):1761–1770PubMedGoogle Scholar
  76. 76.
    Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR (2008) Panton–Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 198(8):1166–1170PubMedGoogle Scholar
  77. 77.
    Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF (2010) Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton–Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A 107(12):5587–5592PubMedGoogle Scholar
  78. 78.
    Lipinska U, Hermans K, Meulemans L, Dumitrescu O, Badiou C, Duchateau L, Haesebrouck F, Etienne J, Lina G (2011) Panton–Valentine leukocidin does play a role in the early stage of Staphylococcus aureus skin infections: a rabbit model. PLoS One 6(8):e22864PubMedGoogle Scholar
  79. 79.
    Kobayashi SD, Malachowa N, Whitney AR, Braughton KR, Gardner DJ, Long D, Bubeck Wardenburg J, Schneewind O, Otto M, Deleo FR (2011) Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J Infect Dis 204(6):937–941PubMedGoogle Scholar
  80. 80.
    Yoong P, Pier GB (2010) Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci U S A 107(5):2241–2246PubMedGoogle Scholar
  81. 81.
    Rasigade JP, Sicot N, Laurent F, Lina G, Vandenesch F, Etienne J (2011) A history of Panton–Valentine leukocidin (PVL)-associated infection protects against death in PVL-associated pneumonia. Vaccine 29(25):4185–4186PubMedGoogle Scholar
  82. 82.
    Bubeck Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O (2007) Poring over pores: alpha-hemolysin and Panton–Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 13(12):1405–1406PubMedGoogle Scholar
  83. 83.
    Kennedy AD, Bubeck Wardenburg J, Gardner DJ, Long D, Whitney AR, Braughton KR, Schneewind O, DeLeo FR (2010) Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 202(7):1050–1058PubMedGoogle Scholar
  84. 84.
    Wang R, Braughton KR, Kretschmer D, Bach TH, Queck SY, Li M, Kennedy AD, Dorward DW, Klebanoff SJ, Peschel A, Deleo FR, Otto M (2007) Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 13(12):1510–1514PubMedGoogle Scholar
  85. 85.
    Ventura CL, Malachowa N, Hammer CH, Nardone GA, Robinson MA, Kobayashi SD, DeLeo FR (2010) Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. PLoS One 5(7):e11634PubMedGoogle Scholar
  86. 86.
    Gillet Y, Dumitrescu O, Tristan A, Dauwalder O, Javouhey E, Floret D, Vandenesch F, Etienne J, Lina G (2011) Pragmatic management of Panton–Valentine leukocidin-associated staphylococcal diseases. Int J Antimicrob AgentsGoogle Scholar
  87. 87.
    Dumitrescu O, Badiou C, Bes M, Reverdy ME, Vandenesch F, Etienne J, Lina G (2008) Effect of antibiotics, alone and in combination, on Panton–Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect 14(4):384–388PubMedGoogle Scholar
  88. 88.
    Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y, Reverdy ME, Vandenesch F, Etienne J, Lina G (2007) Effect of antibiotics on Staphylococcus aureus producing Panton–Valentine leukocidin. Antimicrob Agents Chemother 51(4):1515–1519PubMedGoogle Scholar
  89. 89.
    Joo HS, Chan JL, Cheung GY, Otto M (2010) Subinhibitory concentrations of protein synthesis-inhibiting antibiotics promote increased expression of the agr virulence regulator and production of phenol-soluble modulin cytolysins in community-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54(11):4942–4944PubMedGoogle Scholar
  90. 90.
    Rouzic N, Janvier F, Libert N, Javouhey E, Lina G, Nizou JY, Pasquier P, Stamm D, Brinquin L, Pelletier C, Vandenesch F, Floret D, Etienne J, Gillet Y (2010) Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton–Valentine leukocidin genes. J Clin Microbiol 48(5):1952–1955PubMedGoogle Scholar
  91. 91.
    Obando I, Valderrabanos ES, Millan JA, Neth OW (2010) Necrotising pneumonia due to influenza A (H1N1) and community-acquired methicillin-resistant Staphylococcus aureus clone USA300: successful management of the first documented paediatric case. Arch Dis Child 95(4):305–306PubMedGoogle Scholar
  92. 92.
    Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, Bastian JF, Fierer J, Nizet V (2005) Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J Exp Med 202(2):209–215PubMedGoogle Scholar
  93. 93.
    Liu CI, Liu GY, Song Y, Yin F, Hensler ME, Jeng WY, Nizet V, Wang AH, Oldfield E (2008) A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319(5868):1391–1394PubMedGoogle Scholar
  94. 94.
    Holt DC, Holden MT, Tong SY, Castillo-Ramirez S, Clarke L, Quail MA, Currie BJ, Parkhill J, Bentley SD, Feil EJ, Giffard PM (2011) A very early-branching Staphylococcus aureus lineage lacking the carotenoid pigment staphyloxanthin. Genome Biol Evol 3:881–895PubMedGoogle Scholar
  95. 95.
    Day NPJ, Moore CE, Enright MC, Berendt AR, Smith JM, Murphy MF, Peacock SJ, Spratt BG, Feil EJ (2001) A link between virulence and ecological abundance in natural populations of Staphylococcus aureus. Science 292(5514):114–116PubMedGoogle Scholar
  96. 96.
    Day NP, Moore CE, Enright MC, Berendt AP, Smith JM, Murphy MF, Peacock SJ, Spratt BG, Feil EJ (2002) Retraction. Science 295(5557):971PubMedGoogle Scholar
  97. 97.
    Melles DC, Gorkink RF, Boelens HA, Snijders SV, Peeters JK, Moorhouse MJ, van der Spek PJ, van Leeuwen WB, Simons G, Verbrugh HA, van Belkum A (2004) Natural population dynamics and expansion of pathogenic clones of Staphylococcus aureus. J Clin Invest 114(12):1732–1740PubMedGoogle Scholar
  98. 98.
    Fowler VG Jr, Nelson CL, McIntyre LM, Kreiswirth BN, Monk A, Archer GL, Federspiel J, Naidich S, Remortel B, Rude T, Brown P, Reller LB, Corey GR, Gill SR (2007) Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis 196(5):738–747PubMedGoogle Scholar
  99. 99.
    Xiong YQ, Fowler VG, Yeaman MR, Perdreau-Remington F, Kreiswirth BN, Bayer AS (2009) Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J Infect Dis 199(2):201–208PubMedGoogle Scholar
  100. 100.
    Nienaber JJ, Sharma Kuinkel BK, Clarke-Pearson M, Lamlertthon S, Park L, Rude TH, Barriere S, Woods CW, Chu VH, Marin M, Bukovski S, Garcia P, Corey GR, Korman T, Doco-Lecompte T, Murdoch DR, Reller LB, Fowler VG Jr (2011) Methicillin-Susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins. J Infect Dis 204(5):704–713PubMedGoogle Scholar
  101. 101.
    Deleo FR, Kennedy AD, Chen L, Bubeck Wardenburg J, Kobayashi SD, Mathema B, Braughton KR, Whitney AR, Villaruz AE, Martens CA, Porcella SF, McGavin MJ, Otto M, Musser JM, Kreiswirth BN (2011) Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureus. Proc Natl Acad Sci U S A 108(44):18091–18096Google Scholar
  102. 102.
    Kennedy AD, Otto M, Braughton KR, Whitney AR, Chen L, Mathema B, Mediavilla JR, Byrne KA, Parkins LD, Tenover FC, Kreiswirth BN, Musser JM, DeLeo FR (2008) Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc Natl Acad Sci U S A 105(4):1327–1332PubMedGoogle Scholar
  103. 103.
    Lower SK, Lamlertthon S, Casillas-Ituarte NN, Lins RD, Yongsunthon R, Taylor ES, Dibartola AC, Edmonson C, McIntyre LM, Reller LB, Que YA, Ros R, Lower BH, Fowler VG Jr (2011) Polymorphisms in fibronectin binding protein A of Staphylococcus aureus are associated with infection of cardiovascular devices. Proc Natl Acad Sci U S A. [Epub ahead of print] PubMed PMID: 22025727Google Scholar
  104. 104.
    Shea PR, Beres SB, Flores AR, Ewbank AL, Gonzalez-Lugo JH, Martagon-Rosado AJ, Martinez-Gutierrez JC, Rehman HA, Serrano-Gonzalez M, Fittipaldi N, Ayers SD, Webb P, Willey BM, Low DE, Musser JM (2011) Distinct signatures of diversifying selection revealed by genome analysis of respiratory tract and invasive bacterial populations. Proc Natl Acad Sci U S A 108(12):5039–5044PubMedGoogle Scholar
  105. 105.
    Graham PL III, Lin SX, Larson EL (2006) A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med 144(5):318–325PubMedGoogle Scholar
  106. 106.
    Big C, Malani PN (2010) Staphylococcus aureus bloodstream infections in older adults: clinical outcomes and risk factors for in-hospital mortality. J Am Geriatr Soc 58(2):300–305PubMedGoogle Scholar
  107. 107.
    Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK, for the Active Bacterial Core surveillance MRSA Investigators (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15):1763–1771PubMedGoogle Scholar
  108. 108.
    Centers for Disease Control and Prevention (2003) Methicillin-resistant Staphylococcus aureus infections in correctional facilities—Georgia, California, and Texas, 2001–2003. MMWR Morb Mortal Wkly Rep 52(41):992–996Google Scholar
  109. 109.
    Aiello AE, Lowy FD, Wright LN, Larson EL (2006) Meticillin-resistant Staphylococcus aureus among US prisoners and military personnel: review and recommendations for future studies. Lancet Infect Dis 6(6):335–341PubMedGoogle Scholar
  110. 110.
    Kirkland EB, Adams BB (2008) Methicillin-resistant Staphylococcus aureus and athletes. J Am Acad Dermatol 59(3):494–502PubMedGoogle Scholar
  111. 111.
    Suh L, Coffin S, Leckerman KH, Gelfand JM, Honig PJ, Yan AC (2008) Methicillin-resistant Staphylococcus aureus colonization in children with atopic dermatitis. Pediatr Dermatol 25(5):528–534PubMedGoogle Scholar
  112. 112.
    Begier EM, Frenette K, Barrett NL, Mshar P, Petit S, Boxrud DJ, Watkins-Colwell K, Wheeler S, Cebelinski EA, Glennen A, Nguyen D, Hadler JL (2004) A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns. Clin Infect Dis 39(10):1446–1453PubMedGoogle Scholar
  113. 113.
    Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, Boo T, McAllister S, Anderson J, Jensen B, Dodson D, Lonsway D, McDougal LK, Arduino M, Fraser VJ, Killgore G, Tenover FC, Cody S, Jernigan DB (2005) A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 352(5):468–475PubMedGoogle Scholar
  114. 114.
    Centers for Disease Control and Prevention (2006) Methicillin-resistant Staphylococcus aureus skin infections among tattoo recipients—Ohio, Kentucky, and Vermont, 2004–2005. MMWR Morb Mortal Wkly Rep 55(24):677–679Google Scholar
  115. 115.
    Moreillon P, Que Y, Glauser M (2005) Staphylococcus aureus (including staphylococcal toxic shock). In: Mandell G, Bennett J, Dolin R (eds) Principles and practice of infectious diseases, 6th edn. Churchill Livingstone, Philadelphia, p 2321Google Scholar
  116. 116.
    Miller LS, Cho JS (2011) Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol 11(8):505–518PubMedGoogle Scholar
  117. 117.
    Mathews WC, Caperna JC, Barber RE, Torriani FJ, Miller LG, May S, McCutchan JA (2005) Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr 40(2):155–160PubMedGoogle Scholar
  118. 118.
    Jacobsson G, Dashti S, Wahlberg T, Andersson R (2007) The epidemiology of and risk factors for invasive Staphylococcus aureus infections in western Sweden. Scand J Infect Dis 39(1):6–13PubMedGoogle Scholar
  119. 119.
    Mowat A, Baum J (1971) Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 284(12):621–627PubMedGoogle Scholar
  120. 120.
    Schentag JJ, Hyatt JM, Carr JR, Paladino JA, Birmingham MC, Zimmer GS, Cumbo TJ (1998) Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis 26(5):1204–1214PubMedGoogle Scholar
  121. 121.
    Harinstein L, Schafer J, D’Amico F (2011) Risk factors associated with the conversion of meticillin-resistant Staphylococcus aureus colonisation to healthcare-associated infection. J Hosp Infect 79(3):194–197PubMedGoogle Scholar
  122. 122.
    Muller AA, Mauny F, Bertin M, Cornette C, Lopez-Lozano JM, Viel JF, Talon DR, Bertrand X (2003) Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin Infect Dis 36(8):971–978PubMedGoogle Scholar
  123. 123.
    Anderson DJ, Chen LF, Schmader KE, Sexton DJ, Choi Y, Link K, Sloane R, Kaye KS (2008) Poor functional status as a risk factor for surgical site infection due to methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 29(9):832–839PubMedGoogle Scholar
  124. 124.
    Manzur A, Gudiol F (2009) Methicillin-resistant Staphylococcus aureus in long-term-care facilities. Clin Microbiol Infect 15(Suppl 7):26–30PubMedGoogle Scholar
  125. 125.
    Fowler VG Jr, Miro JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS (2005) Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293(24):3012–3021PubMedGoogle Scholar
  126. 126.
    Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME (2011) Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence 2(5):445–459PubMedGoogle Scholar
  127. 127.
    Shaklee J, Zerr DM, Elward A, Newland J, Leckerman K, Asti L, Guth R, Bass J, Selvarangan R, Coffin S, Zaoutis T (2011) Improving surveillance for pediatric Clostridium difficile infection: derivation and validation of an accurate case-finding tool. Pediatr Infect Dis J 30(3):e38–e40PubMedGoogle Scholar
  128. 128.
    Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE MJR, Talan DA, Chambers HF (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52(3):285–292PubMedGoogle Scholar
  129. 129.
    Cheng AG, DeDent AC, Schneewind O, Missiakas D (2011) A play in four acts: Staphylococcus aureus abscess formation. Trends Microbiol 19(5):225–232PubMedGoogle Scholar
  130. 130.
    Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW (1998) Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 42(3):721–724PubMedGoogle Scholar
  131. 131.
    Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C (2005) Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 49(6):2260–2266PubMedGoogle Scholar
  132. 132.
    Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH (2003) Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 124(5):1789–1797PubMedGoogle Scholar
  133. 133.
    Walkey AJ, O’Donnell MR, Wiener RS (2011) Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials. Chest 139(5):1148–1155PubMedGoogle Scholar
  134. 134.
    Gerson SL, Kaplan SL, Bruss JB, Le V, Arellano FM, Hafkin B, Kuter DJ (2002) Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 46(8):2723–2726PubMedGoogle Scholar
  135. 135.
    Legout L, Senneville E, Gomel JJ, Yazdanpanah Y, Mouton Y (2004) Linezolid-induced neuropathy. Clin Infect Dis 38(5):767–768PubMedGoogle Scholar
  136. 136.
    Lawrence KR, Adra M, Gillman PK (2006) Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 42(11):1578–1583PubMedGoogle Scholar
  137. 137.
    Farrell DJ, Mendes RE, Ross JE, Sader HS, Jones RN (2011) LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States. Antimicrob Agents Chemother 55(8):3684–3690PubMedGoogle Scholar
  138. 138.
    Morales G, Picazo JJ, Baos E, Candel FJ, Arribi A, Pelaez B, Andrade R, de la Torre MA, Fereres J, Sanchez-Garcia M (2010) Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 50(6):821–825PubMedGoogle Scholar
  139. 139.
    Wilson P, Andrews JA, Charlesworth R, Walesby R, Singer M, Farrell DJ, Robbins M (2003) Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 51(1):186–188PubMedGoogle Scholar
  140. 140.
    Gao W, Chua K, Davies JK, Newton HJ, Seemann T, Harrison PF, Holmes NE, Rhee HW, Hong JI, Hartland EL, Stinear TP, Howden BP (2010) Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog 6(6):e1000944PubMedGoogle Scholar
  141. 141.
    Greer ND (2006) Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 19(2):155–161Google Scholar
  142. 142.
    Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H (2008) Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 62(Suppl 1):i17–i28PubMedGoogle Scholar
  143. 143.
    DiMondi VP, Drew RH, Chen LF (2011) Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy. Expert Rev Anti Infect Ther 9(8):567–572PubMedGoogle Scholar
  144. 144.
    Jacqueline C, Amador G, Batard E, Le Mabecque V, Miegeville AF, Biek D, Caillon J, Potel G (2011) Comparison of ceftaroline fosamil, daptomycin and tigecycline in an experimental rabbit endocarditis model caused by methicillin-susceptible, methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. J Antimicrob Chemother 66(4):863–866PubMedGoogle Scholar
  145. 145.
    Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D (2010) Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 51(6):641–650PubMedGoogle Scholar
  146. 146.
    File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley I, Thye D (2010) Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 51(12):1395–1405PubMedGoogle Scholar
  147. 147.
    Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI (2004) The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 38(12):1673–1681PubMedGoogle Scholar
  148. 148.
    Krige JE, Lindfield K, Friedrich L, Otradovec C, Martone WJ, Katz DE, Tally F (2007) Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. Curr Med Res Opin 23(9):2147–2156PubMedGoogle Scholar
  149. 149.
    Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355(7):653–665PubMedGoogle Scholar
  150. 150.
    Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191(12):2149–2152PubMedGoogle Scholar
  151. 151.
    van Hal SJ, Paterson DL, Gosbell IB (2011) Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient—a review of the literature. Eur J Clin Microbiol Infect Dis 30(5):603–610PubMedGoogle Scholar
  152. 152.
    Kelley PG, Gao W, Ward PB, Howden BP (2011) Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 66(5):1057–1060PubMedGoogle Scholar
  153. 153.
    Stryjewski ME, Graham DR, Wilson SE, O’Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR (2008) Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 46(11):1683–1693PubMedGoogle Scholar
  154. 154.
    Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME (2011) Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis 52(1):31–40PubMedGoogle Scholar
  155. 155.
    Verkaik NJ, van Wamel WJ, van Belkum A (2011) Immunotherapeutic approaches against Staphylococcus aureus. Immunotherapy 3(9):1063–1073PubMedGoogle Scholar
  156. 156.
    Schaffer AC, Lee JC (2009) Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am 23(1):153–171PubMedGoogle Scholar
  157. 157.
    Broughan J, Anderson R, Anderson AS (2011) Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines. Expert Rev Vaccine 10(5):695–708Google Scholar
  158. 158.
    Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R (2002) Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 346(7):491–496PubMedGoogle Scholar
  159. 159.
    Harro C, Betts R, Orenstein W, Kwak EJ, Greenberg HE, Onorato MT, Hartzel J, Lipka J, DiNubile MJ, Kartsonis N (2010) Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin Vaccine Immunol 17(12):1868–1874PubMedGoogle Scholar
  160. 160.
    DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, Jung E, Millard D, Schelonka R, Eyal F, Morris A, Kapik B, Roberson D, Kesler K, Patti J, Hetherington S (2007) Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151(3):260–265PubMedGoogle Scholar
  161. 161.
    Weems JJ Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JF, Kubin CJ, Talwani R, Moore T, Patti JM, Hetherington S, Texter M, Wenzel E, Kelley VA, Fowler VG Jr (2006) Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50(8):2751–2755PubMedGoogle Scholar
  162. 162.
    Benjamin DK, Schelonka R, White R, Holley HP, Bifano E, Cummings J, Adcock K, Kaufman D, Puppala B, Riedel P, Hall B, White J, Cotton CM (2006) A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 26(5):290–295PubMedGoogle Scholar
  163. 163.
    Rupp ME, Holley HP Jr, Lutz J, Dicpinigaitis PV, Woods CW, Levine DP, Veney N, Fowler VG Jr (2007) Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51(12):4249–4254PubMedGoogle Scholar
  164. 164.
    Weisman LE, Thackray HM, Steinhorn RH, Walsh WF, Lassiter HA, Dhanireddy R, Brozanski BS, Palmer KG, Trautman MS, Escobedo M, Meissner HC, Sasidharan P, Fretz J, Kokai-Kun JF, Kramer WG, Fischer GW, Mond JJ (2011) A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 128(2):271–279PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Steven Y. C. Tong
    • 1
    • 2
  • Luke F. Chen
    • 1
    • 3
  • Vance G. FowlerJr
    • 1
    • 4
  1. 1.Division of Infectious Diseases and International HealthDuke University Medical CenterDurhamUSA
  2. 2.Menzies School of Health ResearchDarwinAustralia
  3. 3.Duke University Prevention EpicenterDurhamUSA
  4. 4.Duke Clinical Research InstituteDurhamUSA

Personalised recommendations